(September 21, 2023, 9:18 AM EDT) -- WASHINGTON, D.C. — In its second ruling in the case, the Federal Circuit U.S. Court of Appeals on Sept. 20 affirmed findings by a fellow member of its own court, sitting by designation in a federal court in Delaware, that a patent allegedly infringed by the hemophilia drug Hemlibra is invalid for lack of enablement....